Cited by 238Cardiac Fibrosis and RemodelingCongenital heart defects researchTGF-β signaling in diseases

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

A transcriptional switch governs fibroblast activation in heart disease

Open access

Published version of a preprint

Abstract

In diseased organs, stress-activated signalling cascades alter chromatin, thereby triggering maladaptive cell state transitions. Fibroblast activation is a common stress response in tissues that worsens lung, liver, kidney and heart disease, yet its mechanistic basis remains unclear 1,2. Pharmacological inhibition of bromodomain and extra-terminal domain (BET) proteins alleviates cardiac dysfunction 3-7, providing a tool to interrogate and modulate cardiac cell states as a potential therapeutic approach. Here we use single-cell epigenomic analyses of hearts dynamically exposed to BET inhibitors to reveal a reversible transcriptional switch that underlies the activation of fibroblasts. Resident cardiac fibroblasts demonstrated robust toggling between the quiescent and activated state in a manner directly correlating with BET inhibitor exposure and cardiac function. Single-cell chromatin accessibility revealed previously undescribed DNA elements, the accessibility of which dynamically correlated with cardiac performance. Among the most dynamic elements was an enhancer that regulated the transcription factor MEOX1, which was specifically expressed in activated fibroblasts, occupied putative regulatory elements of a broad fibrotic gene program and was required for TGFβ-induced fibroblast activation. Selective CRISPR inhibition of the single most dynamic cis-element within the enhancer blocked TGFβ-induced Meox1 activation. We identify MEOX1 as a central regulator of fibroblast activation associated with cardiac dysfunction and demonstrate its upregulation after activation of human lung, liver and kidney fibroblasts. The plasticity and specificity of BET-dependent regulation of MEOX1 in tissue fibroblasts provide previously unknown trans- and cis-targets for treating fibrotic disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-021-03674-1

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 53 references

Cited by

Sorted by citations

Items 101–200 of 237

Metadata

Authors
Alexanian, M., Przytycki, P. F., Micheletti, R., Padmanabhan, A., Ye, L., Travers, J. G., Gonzalez-Teran, B., Silva, A. C., Duan, Q., Ranade, S. S., Felix, F., Linares-Saldana, R., Li, L., Lee, C. Y., Sadagopan, N., Pelonero, A., Huang, Y., Andreoletti, G., Jain, R., McKinsey, T. A., Rosenfeld, M. G., Gifford, C. A., Pollard, K. S., Haldar, S. M., & Srivastava, D.
Affiliations
  • Gladstone Institutes (US)
  • Howard Hughes Medical Institute (US)
  • University of Colorado Anschutz (US)
  • University of Pennsylvania (US)
  • University of California, San Francisco (US)
  • Amgen (United States) (US)
Corresponding author
  • Haldar, Saptarsi M.
  • Srivastava, Deepak
Venue
Nature
Published
2021-06-23
Volume
595
Issue
7867
Pages
438-443
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W3176137376
Cited by
238
References
53
Citations by year
2026: 43 · 2025: 48 · 2024: 47 · 2023: 39 · 2022: 45 · 2021: 13
FWCI
24.11
Type
journal article
Language
en
Open access
Locations
  • Nature (publishedVersion)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • National Science Foundation
  • American Heart Association (18POST34080175, 16SFRN31400013)
  • A.P. Giannini Foundation (P0527061)
  • Tobacco-Related Disease Research Program (578649)
  • Gladstone Institutes
  • Giannini Foundation of Agricultural Economics (P0527061)
  • Roddenberry Foundation
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (186704)
  • National Institutes of Health (16SFRN31400013, P01 HL098707, 1c06rr018928-01, HL146366, HL098179)
  • Agency for Healthcare Research and Quality (R01HS015100)
  • National Heart, Lung, and Blood Institute (F32HL147463, R01HL147558, R01HL116848, R01HL139783, P01HL146366, UM1HL098179, R01HL150100, P01HL089707, R01HL127240, R01HL150521, U01HL098179, R01HL150225, R01HL057181, K08HL157700)
  • National Institute of Mental Health (R01MH123178)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK119594)
  • National Center for Research Resources (C06-RR-018928, RR018928)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Congenital heart defects research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
Keywords
fibroblast activation, cardiac fibroblasts, BET proteins, MEOX1, transcriptional switch, chromatin accessibility, enhancers, TGF-beta signaling, myocardial fibrosis, cardiac dysfunction, fibrotic diseases, BET inhibitors, cis-regulatory elements, single-cell epigenomics
MeSH terms
Bromodomain Containing Proteins, Animals, Chromatin, Enhancer Elements, Genetic, Fibroblasts, Gene Expression Regulation, Heart Diseases, Humans, Proteins, Transcription Factors, Transforming Growth Factor beta, Homeodomain Proteins, Mice, Epigenomics, Single-Cell Analysis, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review